Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 110
Summary
- Conditions
- Breast Adenocarcinoma
- Breast Cancer
- Breast Cancer - Female
- Breast Neoplasms
- Cancer Breast
- ER Positive
- Estrogen Receptor Positive Tumor
- Estrogen Receptor Positive Breast Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03250676
- Collaborators
- Eisai Inc.
- Investigators
- Not Provided